Cystic fibrosis pulmonary exacerbation: Difference between revisions
From IDWiki
(Imported from text file) |
m (Text replacement - "Clinical Presentation" to "Clinical Manifestations") |
||
| Line 1: | Line 1: | ||
== Clinical |
== Clinical Manifestations == |
||
* Increased cough and sputum production |
* Increased cough and sputum production |
||
Revision as of 02:33, 21 July 2020
Clinical Manifestations
- Increased cough and sputum production
- Increased dyspnea
- Poor appetite, weight loss, occasionally fever, fatigue, reduction in pulmonary function, increased hemoptysis, change in chest radiographic findings, or change in chest physical examination findings (increased rales or rhonchi, decreased air exchange, increased use of accessory muscles of respiration)
Management
- Get sputum cultures
- See Cystic fibrosis (CF) antibiotic dosing
- Burkholderia cepacia
- Most important organism to cover, if present
- Meropenem, ceftazidime, tobi, doxy, Septra, levo
- Pseudomonas
- Double coverage
- Beta-lactam plus another (quinolone, colistin, chloramphenicol, aminoglycoside)
- Treat for 10-14 days and repeat FPTs
- Stenotrophomonas
- Septra, doxycycline, tigecycline, colistin, sometimes levofloxacin
- Staph. aureus
- MSSA: cloxacillin, ceftazidime, Septra, doxycycline, meropenem
- MRSA: vancomycin, tigecycline, linezolid, daptomycin, doxycycline, Septra
